On Wednesday, Following Stocks were among the “Top Priority Stocks” For Traders - KLA-Tencor (NASDAQ:KLAC), Alkermes (NASDAQ:ALKS), Tower Semiconductor (USA) (NASDAQ:TSEM), PTC Therapeutics, (NASDAQ:PTCT)
KLA-Tencor Corp (NASDAQ:KLAC) fell -5.72%, and closed at $59.37. The stock has the beta value of 1.52, and its volatility for the week is 2.30%, while for the month it is 1.85%. The company has the market capitalization of $10.24 B. The company holds the book value per share of 3.67, whereas cash per share is 14.55. Price to book ratio remained 16.18, while price to sale ratio is 3.35. Analysts mean recommendation for the stock is said to be 2.70 (where 1=Buy, 5=sale).
KLA-Tencor Corp (KLAC) manufactures, and markets process control and yield management solutions worldwide. It provides chip manufacturing products, including front-end defect inspection, back-end defect inspection, defect review, metrology, and in-situ process monitoring products, as well as lithography modeling software; wafer manufacturing products comprising surface and defect inspection, wafer geometry and nanotopography metrology, and data management; and reticle manufacturing products, such as defect inspection and pattern placement metrology products.
Alkermes Plc (NASDAQ:ALKS) decreased -5.76%, and closed at $62.46. The stock has price to sale ratio of 14.95, however, price to book ratio is 6.57. With recent decline, the year-to-date (YTD) performance reflected a 7.54% incline below last year. During the past month the stock lose -12.16%, bringing three-month performance to 11.22% and six-month performance to 45.9%. The mean recommendation of analysts for this stock is 2.30 (where 1=Buy, 5=Sale).
Alkermes Plc (ALKS) an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence.
Tower Semiconductor Ltd. (USA) (NASDAQ:TSEM) declined –5.65%, and closed at $16.53. The company has the market capitalization of $1.02 billion. The beta value of the stock is 1.36. On the other hand the stock’s volatility for the week is 3.60%, and for the month is 3.36%. The stock’s price to book ratio is $4.49, however price to sale ratio is $1.16. Analyst’s mean recommendation regarding this stock is 2.00. (Where 1=Buy, 5=Sale).
Tower Semiconductor Ltd. (USA) (TSEM) an independent semiconductor foundry, manufactures analog intensive mixed-signal semiconductor devices in the United States, Asia, and Europe. It produces integrated circuits (IC) primarily based on third party designs and proprietary designs with geometries ranging from 1.0 to 0.11 micron, as well as provides design and technical services. The company also offers a range of customizable process technologies, including SiGe, BiCMOS, mixed-signal and RFCMOS, CMOS image sensor, power management, and non-volatile memory, as well as MEMS capabilities.
PTC Therapeutics, Inc. (NASDAQ:PTCT) shares picked down -5.77%, and closed at $62.22. The stock volatility for the week is 6.01%, while for the month remained 5.46%. The company holds consensus target price of $88.50.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -3.03 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 42.70% and Annual EPS growth for the past 5 years is considered as -6.40%.
The mean recommendation of analysts for this stock is 1.80. (Where 1=Buy, 5=Sale).
PTC Therapeutics, Inc. (PTCT) a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companys lead product is Translarna (ataluren), which is in Phase III clinical trials for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and for the treatment of cystic fibrosis caused by nonsense mutations. It also intends to develop Translarna for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, as well as develops spinal muscular atrophy, which is in Phase II clinical program.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
